Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting HER2-positive breast cancer: advances and future directions
Sandra M. Swain, Mythili Shastry, Erika Hamilton
Nature Reviews Drug Discovery (2022) Vol. 22, Iss. 2, pp. 101-126
Open Access | Times Cited: 527

Showing 26-50 of 527 citing articles:

Research progress in tumor angiogenesis and drug resistance in breast cancer
Jiancheng Mou, Chenhong Li, Qinghui Zheng, et al.
Cancer Biology and Medicine (2024), pp. 1-15
Open Access | Times Cited: 14
Research Progress of SN38 Drug Delivery System in Cancer Treatment
Qing-rui Qi, Huan Tian, Baosen Yue, et al.
International Journal of Nanomedicine (2024) Vol. Volume 19, pp. 945-964
Open Access | Times Cited: 13
Analytical validation of HER2DX genomic test for early-stage HER2-positive breast cancer
Mercedes Marín‐Aguilera, Pedro Jares, Esther Sanfeliu, et al.
ESMO Open (2024) Vol. 9, Iss. 3, pp. 102903-102903
Open Access | Times Cited: 13
HER2/PI3K/AKT pathway in HER2-positive breast cancer: A review
Linghui Pan, Jinling Li, Qi Xu, et al.
Medicine (2024) Vol. 103, Iss. 24, pp. e38508-e38508
Open Access | Times Cited: 13
Tyrosine phosphorylation-mediated YAP1-TFAP2A interactions coordinate transcription and trastuzumab resistance in HER2+ breast cancer
Hailin Zou, Juan Luo, Yibo Guo, et al.
Drug Resistance Updates (2024) Vol. 73, pp. 101051-101051
Open Access | Times Cited: 12
Development and evaluation of a human CD47/HER2 bispecific antibody for Trastuzumab-resistant breast cancer immunotherapy
Binglei Zhang, Jianxiang Shi, Xiaojing Shi, et al.
Drug Resistance Updates (2024) Vol. 74, pp. 101068-101068
Closed Access | Times Cited: 12
Mini-Review: Current Bladder Cancer Treatment—The Need for Improvement
Emily Gill, Claire M. Perks
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 3, pp. 1557-1557
Open Access | Times Cited: 10
Systemically administered low-affinity HER2 CAR T cells mediate antitumor efficacy without toxicity
Tamer B. Shabaneh, Andrew R. Stevens, Sylvia M. Stull, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 2, pp. e008566-e008566
Open Access | Times Cited: 10
Unveiling Alterations of Epigenetic Modifications and Chromatin Architecture Leading to Lipid Metabolic Reprogramming during the Evolutionary Trastuzumab Adaptation of HER2‐Positive Breast Cancer
Ningjun Duan, Yijia Hua, Xueqi Yan, et al.
Advanced Science (2024) Vol. 11, Iss. 18
Open Access | Times Cited: 10
Novel therapeutic strategies for rare mutations in non-small cell lung cancer
Qitao Gou, Qiheng Gou, Xiaochuan Gan, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 10
Revolutionizing Cancer Treatment: Recent Advances in Immunotherapy
Rose Ghemrawi, Lama Abuamer, Sedra Kremesh, et al.
Biomedicines (2024) Vol. 12, Iss. 9, pp. 2158-2158
Open Access | Times Cited: 10
Aberrant MET Receptor Tyrosine Kinase Signaling in Glioblastoma: Targeted Therapy and Future Directions
Abdulhameed Al‐Ghabkari, Bruce Huang, Morag Park
Cells (2024) Vol. 13, Iss. 3, pp. 218-218
Open Access | Times Cited: 9
Tumor-Targeted Oxaliplatin(IV) Prodrug Delivery Based on ROS-Regulated Cancer-Selective Glycan Labeling
Jiajia Wang, Wei Cao, Wei Zhang, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 10, pp. 8296-8308
Closed Access | Times Cited: 9
Lipid rafts, caveolae, and epidermal growth factor receptor family: friends or foes?
Francesca Ruzzi, Chiara Cappello, Maria Sofia Semprini, et al.
Cell Communication and Signaling (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 9
AXL/WRNIP1 Mediates Replication Stress Response and Promotes Therapy Resistance and Metachronous Metastasis in HER2+ Breast Cancer
Mauricio Marquez-Palencia, L Herrera, Pravat Kumar Parida, et al.
Cancer Research (2024) Vol. 84, Iss. 5, pp. 675-687
Open Access | Times Cited: 8
Folic acid-functionalized PEGylated niosomes co-encapsulated cisplatin and doxoribicin exhibit enhanced anticancer efficacy
Mona Safari Sharafshadeh, Farzaneh Tafvizi, Parvin Khodarahmi, et al.
Cancer Nanotechnology (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 8
Standard-of-Care Treatment for HER2+ Metastatic Breast Cancer and Emerging Therapeutic Options
Sarah Premji, Ciara C. O’Sullivan
Breast Cancer Basic and Clinical Research (2024) Vol. 18
Open Access | Times Cited: 8
Safety Profile of the Trastuzumab-Based ADCs: Analysis of Real-World Data Registered in EudraVigilance
Claudiu Morgovan, Carmen Maximiliana Dobrea, Anca Butucă, et al.
Biomedicines (2024) Vol. 12, Iss. 5, pp. 953-953
Open Access | Times Cited: 8
Affibody PET Imaging of HER2-Expressing Cancers as a Key to Guide HER2-Targeted Therapy
Nina Eißler, Renske Altena, Ali Alhuseinalkhudhur, et al.
Biomedicines (2024) Vol. 12, Iss. 5, pp. 1088-1088
Open Access | Times Cited: 8
Advances in Therapy for Urothelial and Non-Urothelial Subtype Histologies of Advanced Bladder Cancer: From Etiology to Current Development
Whi‐An Kwon, Ho Kyung Seo, Geehyun Song, et al.
Biomedicines (2025) Vol. 13, Iss. 1, pp. 86-86
Open Access | Times Cited: 1
Synthesis and Anticancer Evaluation of O-Alkylated (E)-Chalcone Derivatives: A Focus on Estrogen Receptor Inhibition
Alwah R. Al-Ghamdi, Wahid U. Ahmed, Reem I. Al-Wabli, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 2, pp. 833-833
Open Access | Times Cited: 1
An update on promising and emerging protein kinase B/AKT inhibitors for breast cancer
Riccardo Asnaghi, Gabriele Antonarelli, Elena Battaiotto, et al.
Expert Opinion on Pharmacotherapy (2025)
Open Access | Times Cited: 1
Comprehensive insights into pathogenicity and emerging CRISPR-integrated biosensors for the early detection of breast cancer biomarkers
Ashok Saini, Neeraj Dilbaghi, Neelam Yadav
Microchemical Journal (2025), pp. 112908-112908
Closed Access | Times Cited: 1
Pharmacological targeting of ECM homeostasis, fibroblast activation, and invasion for the treatment of pulmonary fibrosis
Ioannis Tomos, Paraskevi Kanellopoulou, Dimitris Nastos, et al.
Expert Opinion on Therapeutic Targets (2025)
Closed Access | Times Cited: 1
Spatiotemporally resolved mapping of extracellular proteomes via in vivo-compatible TyroID
Zijuan Zhang, Yankun Wang, Wenjie Lu, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 1

Scroll to top